Foxo Technologies Inc (FOXO) News & EventsFOXONews & EventsFoxo Technologies Inc

FOXO Technologies Expands Clinical Capabilities at Scott County Hospital

FOXO Technologies announced that its critical access-designated acute care hospital, Scott County Community Hospital, has expanded its clinical capabilities through the addition of inpatient tele-specialty services and cardiac diagnostics. In partnership with Rural Physicians Group, Big South Fork Medical Center now provides inpatient tele-specialty coverage in cardiology, pulmonology, and nephrology, enabling more patients to receive specialty evaluation and treatment locally. "These additions strengthen our ability to treat patients locally while maintaining appropriate clinical oversight," said Cathal McGuckin, Interim Chief Executive Officer of Big South Fork Medical Center. "Tele-specialty support, combined with expanded diagnostics, improves care access and reduces unnecessary patient transfers."

Foxo Technologies Completes Acquisition of Vector Biosource

FOXO Technologies announces the closing of the acquisition of Vector Biosource. Vector is an information, data and biospecimen sourcing provider serving the biotechnology, clinical research and pharmaceutical research industries. Vector generated second quarter 2025 net revenues of approximately $225,000 and is expected to grow significantly post-acquisition. The purchase price consists of: $500,000 in cash, 60,000 shares of the Company's Series E Cumulative Redeemable Secured Preferred Stock, warrants to purchase $2 million of the Company's common stock at a 10% premium to the common stock's closing price one day prior to closing, and up to an additional 80,000 shares of Series E Preferred Stock subject to achieving certain revenue and cash collection milestones in a future 12 to 24 month period. In addition, FOXO has agreed to fund up to $1.2 million of Vector's growth initiatives.

Foxo Technologies Signs Deal to Purchase Vector Biosource

FOXO Technologies signed a stock purchase agreement to acquire Vector Biosource. Vector is an information, data and biospecimen sourcing provider serving the biotechnology, clinical research and pharmaceutical research industries. Vector generated second quarter 2025 net revenues of approximately $225,000 and is expected to grow significantly post-acquisition. The expected purchase price consists of: $500,000 in cash, 60,000 shares of the Company's Series E Cumulative Redeemable Secured Preferred Stock, warrants to purchase $2M of the Company's common stock at a 10% premium to the common stock's closing price one day prior to closing, and up to an additional 80,000 shares of Series E Preferred Stock subject to achieving certain revenue and cash collection milestones in a future 12 to 24 month period. Closing is expected to occur as soon as practical after a number of closing conditions are satisfied including, but not limited to, completion of due diligence and forms of warrant and employment agreements being finalized. In addition, FOXO has agreed to fund up to $1.2M of Vector's growth initiatives.